Predictive model for plasma concentration-versus-time profiles of investigational anticancer drugs in patientsi

Journal of the National Cancer Institute

Volumn 80, Issue 11, 1988, Pages 815-819

  Davis, Lisa E ^a,b   Alberts, David S ^a,b   Plezia, Patricia M ^a,b   Roe, Denise J ^a   Griswold, Daniel P ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BLOOD LEVEL; CANCER CHEMOTHERAPY; DRUG DOSE; DRUG THERAPY; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ANIMAL; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; HUMAN; MICE; MICE, INBRED STRAINS; MODELS, BIOLOGICAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023695920     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/80.11.815     Document Type: Article

References (15)

1. Collins JM, Zaharko DS, Dedrick RL, et al. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 1986;70:73-80.
2. Scheithauer W, Clark GM, Moyer MP, et al. New screening system for selection of anticancer drugs for treatment of human colorectal cancer. Cancer Res 1986;46:2703-2708.
3. Scheithauer W, Clark GM, Salmon SE, et al. Model for estimation of clinically achievable plasma concentrations for investigational anti-cancer drugs in man. Cancer Treat Rep 1986;70:1379-1382.
4. Guarino AM, Rozencweig M, Kline I, et al. Adequacies and inadequacies in assessing murine toxicity data with antineoplastic agents. Cancer Res 1979;39:2204-2210.
5. Alberts DS, Chen HS. Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In: Salmon SE, ed. Cloning of human tumor cells. New York: Liss, 1980:351-359.
6. Sommadossi JP, Aubert C, Cano JP, et al. Kinetics and metabolism of a new fluoropyrimidine, 5-deoxy-5-fluorouridine, in humans. Cancer Res 1983;43:930-933.
7. Marsh KC, Liesmann J, Patton TF, et al. Plasma levels and urinary excretion of methyl-GAG following iv infusion in man. Cancer Treat Rep 1981;65:253-257.
8. Snedecor GW, Cochran WG. Statistical methods. Ames, IA: The Iowa State University Press, 1967.
9. Freireich EJ, Gehan EA, Raul DP, et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-245.
10. Goldsmith MA, Slavik M, Carter SK. Quantitative prediction of drug toxicity in humans in small and large animals. Cancer Res 1975;35:1354-1364.
11. Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 1986;75:1028-1040.
12. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982;10:201-227.
13. Dedrick RL, Bischoff KB, Zaharko DS. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 1970;54:95-101.
14. Powis G. Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man. Drug Metab Rev 1983;14:1145-1163.
15. Nichol CA. Pharmacokinetics. Selectivity of action related to physio-chemical properties and kinetic patterns of anticancer drugs. Cancer 1977;40:519-528.